Tavexia Lifecare fixes AGM date; seeks ₹100 crore RPT approval

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights
  • Tavexia Lifecare schedules 46th AGM for September 30, 2026
  • Board seeks approval for ₹100 crore related-party transaction limit
  • New statutory auditor DEVAM & Associates LLP appointed for five years
  • Company plans to acquire up to 60% stake in Meyonex Pharmaceuticals
powered bylight_fuzz_icon
50341374

*this image is generated using AI for illustrative purposes only.

Tavexia Lifecare Limited has scheduled its 46th Annual General Meeting (AGM) for Wednesday, September 30, 2026, at 12:00 pm via Video Conferencing. The company has published the AGM notice in compliance with SEBI LODR Regulation 30, confirming the agenda includes adoption of FY25-26 accounts and special business items.

The meeting will address ordinary business including the adoption of FY25-26 accounts and special business involving auditor appointments and related-party transactions. The board previously announced plans to acquire up to a 60% stake in Meyonex Pharmaceuticals Limited. This acquisition proposal was approved during the board meeting on September 7, 2026.

Auditor and Board Changes

Tavexia accepted the resignation of its statutory auditors, M/s SSRV & Associates, effective September 7, 2026. The board appointed M/s DEVAM & Associates LLP as the new statutory auditors for a five-year term from FY27 to FY31, subject to shareholder approval at the upcoming AGM.

Additionally, the board recommended the reappointment of Mrs. Khushboo Vasudev as an independent director for a second five-year term starting December 31, 2026. This appointment also requires shareholder approval.

Related-Party Transaction Limits

The board seeks shareholder approval for material related-party transactions under Section 188 of the Companies Act, 2013. The proposed limit is up to ₹100 crore per related party for transactions including sale/purchase of goods, services, lending, and investments. This cap applies for an 18-month period from April 1, 2026, to September 30, 2027.

Key related parties include:

  • Roshan Dealmark Private Limited (Promoter Company)
  • Mayukh Trading Private Limited (Subsidiary Company)
  • Mit Tarunkumar Brahmabhatt (Managing Director) and his relatives/entities

Key Financials of Target Entity

Particulars Details
Name Meyonex Pharmaceuticals Limited
Authorized Capital ₹20 crore
Paid-up Capital ₹13.99 crore
Industry Pharmaceuticals

Corporate Governance Updates

The board took on record the secretarial audit report for FY25-26 from M/s Brajesh Gupta & Co. It also approved the Board Report, Corporate Governance Report, and Management Discussion and Analysis for the financial year ended March 31, 2026.

Mr. Brajesh Gupta was appointed as the scrutinizer for the e-voting process for the 46th AGM. The book closure period remains fixed from September 24, 2026, to September 30, 2026.

Historical Stock Returns for Sattva Sukun Lifecare

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%-3.36%+13.86%+66.67%+43.75%-67.88%

How might the acquisition of a 60% stake in Meyonex Pharmaceuticals impact Tavexia's revenue mix and market positioning in the pharmaceutical sector?

What are the strategic implications of granting a ₹100 crore related-party transaction limit, and how will this affect minority shareholder confidence?

Could the change in statutory auditors from SSRV & Associates to DEVAM & Associates signal any underlying governance or compliance concerns for FY25-26?

like20
dislike

Sattva Sukun promoter Roshan Dealmark sells 14 lakh shares on-market

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Roshan Dealmark Private Limited sold 14,00,000 equity shares on September 7, 2026
  • Promoter group stake fell from 6.02% to 5.66% following the disposal
  • Puja Agarwal's holding of 80,000 shares remained unchanged
  • Transaction disclosed under SEBI SAST and PIT regulations
powered bylight_fuzz_icon
50391373

*this image is generated using AI for illustrative purposes only.

Sattva Sukun Lifecare Ltd promoter Roshan Dealmark Private Limited disposed of 14,00,000 equity shares through an on-market transaction on September 7, 2026. The sale reduces the promoter group’s aggregate stake in the company to 5.66%.

The disclosure was filed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. Roshan Dealmark is part of the promoter group acting in concert with Puja Agarwal.

Holding Changes

Before the transaction, Roshan Dealmark held 2,30,49,777 shares, while Puja Agarwal held 80,000 shares. The combined promoter group stake stood at 2,31,29,777 shares, representing 6.02% of the total diluted share capital.

Following the disposal, Roshan Dealmark’s holding decreased to 2,16,49,777 shares. Puja Agarwal’s stake remained unchanged at 80,000 shares. The total promoter group holding now stands at 2,17,29,777 shares.

Metric Before Disposal After Disposal
Total Shares Held 2,31,29,777 2,17,29,777
Stake Percentage 6.02% 5.66%
Shares Sold - 14,00,000

The company’s paid-up equity capital remains unchanged at ₹38,36,01,248, comprising 383,601,248 shares of ₹1 each. The transaction was executed entirely through on-market trades on the Bombay Stock Exchange.

Historical Stock Returns for Sattva Sukun Lifecare

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%-3.36%+13.86%+66.67%+43.75%-67.88%

What strategic rationale drove Roshan Dealmark to reduce its promoter stake to below 6%, and does this signal a broader exit strategy for the promoter group?

How might this reduction in promoter holding impact the company's credit ratings or future ability to raise debt financing?

Will the decrease in promoter stake trigger any mandatory disclosure requirements or affect the company's listing status on the Bombay Stock Exchange?

like19
dislike

More News on Sattva Sukun Lifecare

1 Year Returns:+43.75%